SCHEMBL30905445

SCHEMBL30905445

NC(=O)NCc1ccc(CNC(=O)[C@H](N)CCCNC(=O)OCc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.58
DPP8 Q6V1X1 3/20 0.54
DPP7 Q9UHL4 3/20 0.54
DPP4 P27487 2/20 0.53
DPP9 Q86TI2 2/20 0.53
SLC1A3 P43003 1/20 0.53
SLC1A1 P43005 1/20 0.53
HTT P42858 1/20 0.52
PLAU P00749 1/20 0.52
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TGM2 P21980 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8120404 0.94 ANPEP (0.63) ANPEPDPP8DPP7DPP4DPP9
Trifluoroacetic Acid SCHEMBL30905260 0.94 ANPEP (0.52) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL8111498 0.92 ANPEP (0.59) ANPEPDPP8DPP7DPP4DPP9
Hydrochloric Acid SCHEMBL17133759 0.90 ANPEP (0.67) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL7321298 0.83 ANPEP (0.71) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL1586968 0.83 DPP8 (0.63) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL1586969 0.83 DPP8 (0.63) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL12668303 0.83 ANPEP (0.61) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL2037306 0.82 SLC1A3 (0.70) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL9656664 0.82 DPP8 (0.64) ANPEPDPP8DPP7DPP4DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622966-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-10-01 EP disclosed
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed
WO-2024112612-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R ANPEP 206/4885DPP8 1642/4885DPP7 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.